LONDON — GSK’s once booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year.
Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for who should get the shot.
It was clear that GSK’s vaccine division would see lower sales this quarter. But sales of the RSV vaccine, called Arexvy, and the company’s shingles vaccine Shingrix were both below analysts’ forecasts.
Continue to STAT+ to read the full story…
LONDON — GSK’s once booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year.
Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for who should get the shot.
It was clear that GSK’s vaccine division would see lower sales this quarter. But sales of the RSV vaccine, called Arexvy, and the company’s shingles vaccine Shingrix were both below analysts’ forecasts.
Continue to STAT+ to read the full story…
